603259 药明康德
已收盘 01-30 15:00:00
资讯
新帖
简况
左手卖子右手减持！药明康德56亿元＂一次性收益＂撑起净利暴增，法案利剑与美国市场“单押”风险
华夏时报网 · 01-26
左手卖子右手减持！药明康德56亿元＂一次性收益＂撑起净利暴增，法案利剑与美国市场“单押”风险
药明康德：公司持续聚焦自身独特的CRDMO业务模式
证券日报 · 01-23
药明康德：公司持续聚焦自身独特的CRDMO业务模式
千亿糖尿病药市场，谁主沉浮？
医药地理 · 01-23
千亿糖尿病药市场，谁主沉浮？
中欧基金葛兰旗下中欧医疗A年报最新持仓，重仓药明康德
证券之星 · 01-22
中欧基金葛兰旗下中欧医疗A年报最新持仓，重仓药明康德
广发基金罗国庆旗下广发中证创新药产业ETF年报最新持仓，重仓药明康德
证券之星 · 01-22
广发基金罗国庆旗下广发中证创新药产业ETF年报最新持仓，重仓药明康德
招商基金侯昊旗下招商国证生物医药年报最新持仓，重仓药明康德
证券之星 · 01-21
招商基金侯昊旗下招商国证生物医药年报最新持仓，重仓药明康德
摩根大通减持药明康德(02359)约251.78万股 每股作价约119.32港元
智通财经 · 01-19
摩根大通减持药明康德(02359)约251.78万股 每股作价约119.32港元
每周股票复盘：药明康德（603259）2025年净利预增102.65%
证券之星 · 01-18
每周股票复盘：药明康德（603259）2025年净利预增102.65%
花旗：维持药明康德(02359)“买入”评级 目标价142港元
智通财经 · 01-15
花旗：维持药明康德(02359)“买入”评级 目标价142港元
【券商聚焦】中泰国际重申药明康德(02359)“买入”评级 指2025年业绩将超预期
金吾财讯 · 01-15
【券商聚焦】中泰国际重申药明康德(02359)“买入”评级 指2025年业绩将超预期
药明康德：与全球前20大制药企业全部建立合作伙伴关系
南方财经网 · 01-15
药明康德：与全球前20大制药企业全部建立合作伙伴关系
全球16%市占率与80个商业化项目：药明康德(02359)坚持做对的事 小分子管线三期及商业化项目已达到167个
智通财经 · 01-15
全球16%市占率与80个商业化项目：药明康德(02359)坚持做对的事 小分子管线三期及商业化项目已达到167个
做难而正确的事：药明康德(02359)为24款GLP-1药物提供支持 满足最迫切临床需求
智通财经 · 01-15
做难而正确的事：药明康德(02359)为24款GLP-1药物提供支持 满足最迫切临床需求
花旗：将药明康德(02359)列入90日上行催化剂观察 目标价142港元
智通财经 · 01-14
花旗：将药明康德(02359)列入90日上行催化剂观察 目标价142港元
里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业
智通财经 · 01-14
里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业
【券商聚焦】越秀证券指恒指连升三日创两月高，金价再创新高
金吾财讯 · 01-14
【券商聚焦】越秀证券指恒指连升三日创两月高，金价再创新高
小摩：药明康德(02359)盈喜胜预期 料市场将有正面反应
智通财经 · 01-14
小摩：药明康德(02359)盈喜胜预期 料市场将有正面反应
药明康德涨6.00%，浦银国际证券二个月前给出“买入”评级，目标价124.40元
证券之星 · 01-13
药明康德涨6.00%，浦银国际证券二个月前给出“买入”评级，目标价124.40元
港股异动 | CRO概念股涨幅居前 药明康德(02359)去年净利预计翻倍 板块有望迎“戴维斯双击”
智通财经 · 01-13
港股异动 | CRO概念股涨幅居前 药明康德(02359)去年净利预计翻倍 板块有望迎“戴维斯双击”
商业航天大面积跌停，AI应用继续大涨
大河财立方 · 01-13
商业航天大面积跌停，AI应用继续大涨
加载更多
公司概况
公司名称：
无锡药明康德新药开发股份有限公司
所属行业：
研究和试验发展
上市日期：
2018-05-08
主营业务：
无锡药明康德新药开发股份有限公司的主营业务是为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务。公司的主要产品是化学业务、测试业务、生物学业务。公司的服务能力和规模在行业处于领先地位,拥有了多项行业领先的技术和能力。
发行价格：
21.60
{"stockData":{"symbol":"603259","market":"SH","secType":"STK","nameCN":"药明康德","latestPrice":95.2,"timestamp":1769756401000,"preClose":98.02,"halted":0,"volume":40250593,"delay":0,"changeRate":-0.0288,"floatShares":2473000000,"shares":2984000000,"eps":5.0249,"marketStatus":"已收盘","change":-2.82,"latestTime":"01-30 15:00:00","open":97.85,"high":98.78,"low":95.2,"amount":3881000000,"amplitude":0.0365,"askPrice":95.21,"askSize":327,"bidPrice":95.2,"bidSize":60,"shortable":0,"etf":0,"ttmEps":5.0249,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769995800000},"marketStatusCode":5,"adr":0,"adjPreClose":98.02,"symbolType":"stock","openAndCloseTimeList":[[1769736600000,1769743800000],[1769749200000,1769756400000]],"highLimit":107.82,"lowLimit":88.22,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2983757155,"isCdr":false,"pbRate":4,"roa":"--","peRate":18.945651,"roe":"19.26%","epsLYR":3.28,"committee":-0.335628,"marketValue":284054000000,"turnoverRate":0.0163,"status":1,"hkstockBrief":{"symbol":"02359","market":"HK","secType":"STK","nameCN":"药明康德","latestPrice":111.2,"timestamp":1769760484005,"preClose":115.6,"halted":0,"volume":4387409,"delay":0,"premium":"+4.06"},"floatMarketCap":235456000000},"requestUrl":"/m/hq/s/603259","defaultTab":"news","newsList":[{"id":"2606217935","title":"左手卖子右手减持！药明康德56亿元＂一次性收益＂撑起净利暴增，法案利剑与美国市场“单押”风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217935","media":"华夏时报网","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606217935?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:05","pubTimestamp":1769429133,"startTime":"0","endTime":"0","summary":"近日，药明康德发布的2025年度业绩预增公告显示，公司预计营收同比增长15.84%，归母净利润同比暴增102.65%，但扣非净利润仅增长32.56%，两者70个百分点的增速差源于资产变卖带来的约55.95亿元非经常性收益。这种模式引发市场对其长期估值逻辑的讨论，市场担忧过度依赖此类操作会导致估值从成长股向价值股偏移。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601263630855477.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601263630855477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","LU2242644610.SGD","LU1046422090.SGD","LU0320764599.SGD","LU2495084118.USD","LU2488822045.USD","LU0052750758.USD","603259","02359","LU1808992512.USD","LU1934453819.USD","BK0216","LU1979443071.USD","LU2125910500.SGD","LU1997245177.USD","LU0708995583.HKD","LU0456842615.SGD","BK1141","LU1997244956.HKD","LU1997245094.SGD","BK1576","BK1583","LU2045819591.USD","LU1969619763.USD"],"gpt_icon":0},{"id":"2605477610","title":"药明康德：公司持续聚焦自身独特的CRDMO业务模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2605477610","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605477610?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:09","pubTimestamp":1769170145,"startTime":"0","endTime":"0","summary":"证券日报网讯1月23日，药明康德在互动平台回答投资者提问时表示，公司持续聚焦自身独特的CRDMO业务模式，高效极致服务全球客户，造福全球病患。通过CRDMO业务模式，公司能够迅速产生行业洞见，及时服务客户新分子需求，保证公司长期发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233629167956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","603259","LU0320764599.SGD","LU0052750758.USD","LU1934453819.USD","02359","LU1808992512.USD","LU2328871848.SGD","LU1997244956.HKD","LU1046422090.SGD","LU2125910500.SGD","LU2488822045.USD","BK0216","LU2242644610.SGD","LU2495084118.USD","LU0708995583.HKD","LU1969619763.USD","LU1979443071.USD","LU0456842615.SGD","BK1576","BK1141","BK1583","LU2045819591.USD","LU1997245177.USD"],"gpt_icon":0},{"id":"2605082284","title":"千亿糖尿病药市场，谁主沉浮？","url":"https://stock-news.laohu8.com/highlight/detail?id=2605082284","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605082284?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:56","pubTimestamp":1769162186,"startTime":"0","endTime":"0","summary":"糖尿病药物作为全球慢病管理的核心治疗手段，其市场规模在持续扩容与迭代，传统药物与新疗法在院内外渠道共同勾勒出该领域格局。中国医药工业信息中心PDB数据显示，2025年Q1-Q3，国内全渠道市场糖尿病治疗药物销售额达887亿元。根据PDB数据显示，近三年糖尿病用药市场呈现连续增长，除MAT22Q3因第六批胰岛素专项集采带来过销售额回落，MAT23Q3、MAT24Q3和MAT25Q3分别增长2.41%、7.83%、4.19%，整体市场增长强劲。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123202432a44e75cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123202432a44e75cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4532","LU0154236417.USD","IE00BZ1G4Q59.USD","02359","IE00BKVL7J92.USD","LU1093756325.SGD","BK4599","BK4585","603259","BK4588","03320","NVO","LU1093756168.USD"],"gpt_icon":1},{"id":"2605460304","title":"中欧基金葛兰旗下中欧医疗A年报最新持仓，重仓药明康德","url":"https://stock-news.laohu8.com/highlight/detail?id=2605460304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605460304?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:58","pubTimestamp":1769079523,"startTime":"0","endTime":"0","summary":"证券之星消息，1月22日中欧基金旗下葛兰 赵磊管理的中欧医疗健康混合型基金公布年报，近1年净值增长率21.99%。其中药明康德持仓占比10.11%，为该基金第一大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200033869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1046422090.SGD","LU1934453819.USD","LU2125910500.SGD","LU2328871848.SGD","BK1576","LU1979443071.USD","LU1969619763.USD","603259","LU2045819591.USD","LU1997245177.USD","BK1583","LU2488822045.USD","LU0320764599.SGD","BK0216","150261","LU0456842615.SGD","LU2242644610.SGD","LU0052750758.USD","02359","LU1808992512.USD","LU0708995583.HKD","LU1997245094.SGD","BK1141","LU1997244956.HKD","LU2495084118.USD"],"gpt_icon":0},{"id":"2605431625","title":"广发基金罗国庆旗下广发中证创新药产业ETF年报最新持仓，重仓药明康德","url":"https://stock-news.laohu8.com/highlight/detail?id=2605431625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605431625?lang=zh_cn&edition=full","pubTime":"2026-01-22 07:18","pubTimestamp":1769037511,"startTime":"0","endTime":"0","summary":"证券之星消息，1月22日广发基金旗下罗国庆管理的广发中证创新药产业交易型开放式指数基金公布年报，近1年净值增长率27.2%。与上一季度相比，该基金前十大重仓股新增泰格医药，艾力斯；并对药明康德增仓59.82万股，为该基金第一大重仓股；信立泰，百利天恒等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"61e778919a4dfe506392481497ed8680","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200004541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0052750758.USD","LU1997244956.HKD","603259","516060","LU2125910500.SGD","BK0216","BK1583","LU0708995583.HKD","LU0456842615.SGD","LU2328871848.SGD","LU1808992512.USD","LU2242644610.SGD","LU1979443071.USD","LU1997245177.USD","LU1046422090.SGD","LU2488822045.USD","LU1969619763.USD","LU2495084118.USD","LU1997245094.SGD","02359","BK1141","LU2045819591.USD","BK1576","LU1934453819.USD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2605141127","title":"招商基金侯昊旗下招商国证生物医药年报最新持仓，重仓药明康德","url":"https://stock-news.laohu8.com/highlight/detail?id=2605141127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605141127?lang=zh_cn&edition=full","pubTime":"2026-01-21 05:29","pubTimestamp":1768944545,"startTime":"0","endTime":"0","summary":"证券之星消息，1月21日招商基金旗下侯昊 许荣漫管理的招商国证生物医药指数基金(LOF)公布年报，近1年净值增长率16.19%。其中药明康德持仓占比9.84%，为该基金第一大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100003045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0708995583.HKD","399441","LU2328871848.SGD","LU1997245094.SGD","LU1808992512.USD","BK0216","LU2125910500.SGD","LU1997244956.HKD","BK1141","LU0320764599.SGD","LU1969619763.USD","603259","LU1934453819.USD","LU2045819591.USD","BK1583","LU1046422090.SGD","BK1576","LU2488822045.USD","LU1997245177.USD","LU2242644610.SGD","161726","LU2495084118.USD","LU0456842615.SGD","LU1979443071.USD","LU0052750758.USD","02359"],"gpt_icon":0},{"id":"2604138627","title":"摩根大通减持药明康德(02359)约251.78万股 每股作价约119.32港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604138627","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604138627?lang=zh_cn&edition=full","pubTime":"2026-01-19 19:17","pubTimestamp":1768821437,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，1月14日，摩根大通减持药明康德(02359)251.7805万股，每股作价119.3249港元，总金额约为3亿港元。减持后最新持股数目约为3364.40万股，最新持股比例为6.59%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131342.USD","BK4581","02359","IE00B1XK9C88.USD","LU1145028129.USD","LU2237443622.USD","LU1496350171.SGD","LU2505996681.GBP","IE00B3S45H60.SGD","LU0211327993.USD","IE00BDCRKT87.USD","LU1720051017.SGD","LU2237443895.HKD","LU0203345920.USD","IE00BBT3K403.USD","LU2125910500.SGD","BK4534","BK4566","LU0971096721.USD","LU1046422090.SGD","LU0267386448.USD","LU2462157665.USD","BK4516","LU0149725797.USD","LU0345769128.USD","LU2054465674.USD","LU2430703178.SGD","LU1363072403.SGD","BK4533","LU2237443465.HKD","IE00BKDWB100.SGD","LU1267930490.SGD","LU0203347892.USD","LU0234572021.USD","BK1141","LU1244550494.USD","LU0320765489.SGD","LU1244550221.USD","LU1988902786.USD","LU0943347566.SGD","IE00BWXC8680.SGD","LU2211815571.USD","BK4550","603259","LU2023250504.SGD","LU2495084118.USD","LU0256863811.USD","LU2023250843.SGD","LU0320765646.SGD","LU1032466523.USD"],"gpt_icon":0},{"id":"2604382928","title":"每周股票复盘：药明康德（603259）2025年净利预增102.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604382928","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604382928?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:06","pubTimestamp":1768669572,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，药明康德报收于104.3元，较上周的99.08元上涨5.27%。本周，药明康德1月14日盘中最高价报106.99元。来自公司公告汇总：药明康德2025年归属净利润预增102.65%，达191.51亿元。业绩披露要点药明康德发布业绩预告，预计2025年全年每股收益约6.7元，同比增幅约104.27%。公司公告汇总无锡药明康德新药开发股份有限公司预计2025年度实现营业收入约4,545,617万元，同比增长15.84%，其中持续经营业务收入同比增长21.40%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1997245094.SGD","BK1583","LU2125910500.SGD","LU1934453819.USD","LU0320764599.SGD","BK1141","LU2045819591.USD","LU1808992512.USD","LU2328871848.SGD","BK0216","BK1576","LU1979443071.USD","LU2488822045.USD","LU0708995583.HKD","LU0456842615.SGD","LU1997244956.HKD","LU2495084118.USD","603259","02359","LU1969619763.USD","LU1997245177.USD","LU2242644610.SGD","LU0052750758.USD","LU1046422090.SGD"],"gpt_icon":0},{"id":"2603711546","title":"花旗：维持药明康德(02359)“买入”评级 目标价142港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603711546","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603711546?lang=zh_cn&edition=full","pubTime":"2026-01-15 15:18","pubTimestamp":1768461483,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，药明康德在核心业务领域保持稳固的市场领导地位，维持药明康德“买入”评级，目标价142港元。GLP-1项目方面，截至2025年第三季度，药明康德在全球临床阶段创新药项目中占有16%的市场份额，目前，公司正在推进24个GLP-1项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02359","603259"],"gpt_icon":0},{"id":"2603162429","title":"【券商聚焦】中泰国际重申药明康德(02359)“买入”评级 指2025年业绩将超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2603162429","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603162429?lang=zh_cn&edition=full","pubTime":"2026-01-15 10:31","pubTimestamp":1768444307,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际研报指，药明康德 发布盈喜公告，预计2025年收入将同比增加15.8%至454.6亿元，股东净利润将同比上涨102.7%至191.5亿元，反映核心业务盈利的Non-IFRS经调整净利润同比增加41.3%至149.6亿元，业绩超预期。该机构在DCF模型中纳入2035E盈利预测，根据调整后DCF模型，目标价上调至145.10港元，重申“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973278","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603259","02359"],"gpt_icon":0},{"id":"2603621809","title":"药明康德：与全球前20大制药企业全部建立合作伙伴关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2603621809","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603621809?lang=zh_cn&edition=full","pubTime":"2026-01-15 09:50","pubTimestamp":1768441825,"startTime":"0","endTime":"0","summary":"【药明康德：与全球前20大制药企业全部建立合作伙伴关系】药明康德（603259.SH/2359.HK）近日在第44届摩根大通医疗健康大会（JPM大会）上披露，自2011年至2025年，药明康德已累计服务超过9000家临床前客户，并与全球前20大制药企业全部建立了长期稳定的合作伙伴关系。截至目前，药明康德公司在亚洲、欧洲和北美拥有超过20个研发与生产基地组成的全球网络。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620072958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU1969619763.USD","LU2242644610.SGD","LU1046422090.SGD","BK1574","LU1997244956.HKD","BK1191","LU0052750758.USD","BK1576","LU0708995583.HKD","LU1997245094.SGD","BK0216","BK1141","LU1979443071.USD","LU2125910500.SGD","LU1997245177.USD","02359","LU2045819591.USD","LU1934453819.USD","01477","LU1808992512.USD","LU0320764599.SGD","LU2488822045.USD","LU0456842615.SGD","LU2328871848.SGD","603259","LU2495084118.USD"],"gpt_icon":0},{"id":"2603962526","title":"全球16%市占率与80个商业化项目：药明康德(02359)坚持做对的事 小分子管线三期及商业化项目已达到167个","url":"https://stock-news.laohu8.com/highlight/detail?id=2603962526","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603962526?lang=zh_cn&edition=full","pubTime":"2026-01-15 08:39","pubTimestamp":1768437570,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年1月14日，药明康德在第44届摩根大通医疗健康大会上发表主题演讲，并更新了公司业务进展。根据公司所披露的数据显示，截止2025年三季度，公司小分子CDMO管线总数达到3430个，占全球临床阶段新药管线的16%，其中三期及商业化项目已达到167个。公司回顾了近年来三期及商业化项目的数量及相应所产生的收入，自22年以来，三期及商业化项目分子从107个增长至167个，涨幅达到56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","LU1979443071.USD","LU0052750758.USD","BK1141","BK1583","LU0708995583.HKD","LU1997245094.SGD","LU1934453819.USD","LU1046422090.SGD","02359","LU0320764599.SGD","BK0216","LU1997245177.USD","LU2488822045.USD","LU1969619763.USD","LU1997244956.HKD","603259","BK1576","LU2242644610.SGD","LU2125910500.SGD","LU2495084118.USD","LU1808992512.USD","LU0456842615.SGD","LU2045819591.USD"],"gpt_icon":0},{"id":"2603252636","title":"做难而正确的事：药明康德(02359)为24款GLP-1药物提供支持 满足最迫切临床需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2603252636","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603252636?lang=zh_cn&edition=full","pubTime":"2026-01-15 08:36","pubTimestamp":1768437386,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年1月14日，药明康德在第44届摩根大通医疗健康大会上公布了其GLP-1类药物管线的最新进展。公司表示，目前公司正为24种GLP-1药物提供支持。根据药明康德所披露的数据显示，截至目前，公司正在研发24款GLP-1药物，涵盖小分子与多肽两类技术路径。持续多年GLP-1类药物短缺或许暴露出核心药品供应链存在不足，这些药物的需求呈现指数级增长，实属历史罕见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2045819591.USD","LU0320764599.SGD","GLP","02359","LU1997244956.HKD","LU2242644610.SGD","LU2495084118.USD","LU1934453819.USD","LU1969619763.USD","BK1583","BK4590","LU1979443071.USD","LU1997245177.USD","BK1576","LU1997245094.SGD","LU2125910500.SGD","LU0708995583.HKD","LU2488822045.USD","BK4144","LU0456842615.SGD","603259","LU0052750758.USD","LU1046422090.SGD","BK1141","BK0216","LU2328871848.SGD","LU1808992512.USD"],"gpt_icon":0},{"id":"2603281662","title":"花旗：将药明康德(02359)列入90日上行催化剂观察 目标价142港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603281662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603281662?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:26","pubTimestamp":1768371992,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，对药明康德(02359)列入90日上行催化剂观察，又指集团将于太平洋时间周三(14日)参加美国一场医疗保健会议并发表演讲。基于全球融资复苏，花旗预计药明康德管理层对今年前景保持乐观，并在3月业绩财报上会给出更清晰的2026年业绩指引及细节。药明康德估值吸引，予其“买入”评级，目标价142港元。该行预计，药明康德强劲的增长前景，将得到来自国内外不断增加的订单量支持，预计得益于其“长尾”策略和创新平台提供差异化服务的支持，中国实验室业务在2020至2023年的销售复合年均增长率达27.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603259","02359"],"gpt_icon":0},{"id":"2603664448","title":"里昂：药明康德(02359)为中国医药CRO或CDMO行业首选 料今年可跑赢同业","url":"https://stock-news.laohu8.com/highlight/detail?id=2603664448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603664448?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:20","pubTimestamp":1768371626,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，展望2026年，相信对中国医疗板块而言，盈利交付将比估值扩张更为重要，料药明康德 有望跑赢同业。该行将药明康德列为中国CRO/CDMO行业的首选。该行维持药明康德“跑赢大市”评级及目标价143.4港元。相较同行，药明康德具备更强的盈利增长可见性：其2025年前三季度订单储备同比增长41%，远高于全球平均约14%，即使在地缘政治风险持续的背景下仍保持强劲增势。该行预计2026年药明康德的订单增速将继续领先全球同行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1979443071.USD","BK4139","BK0188","LU0708995583.HKD","LU2125910500.SGD","02359","BK0010","LU2488822045.USD","LU0052750758.USD","LU0320764599.SGD","LU1046422090.SGD","BK0028","600056","LU2495084118.USD","LU1997245094.SGD","LU1934453819.USD","LU1808992512.USD","BK0250","BK0082","BK1576","CDMO","LU0456842615.SGD","BK1141","BK0175","BK0185","LU2045819591.USD","LU1969619763.USD","LU1997245177.USD","LU2328871848.SGD","LU1997244956.HKD","BK1583","603259","BK0216","LU2242644610.SGD"],"gpt_icon":0},{"id":"2603664476","title":"【券商聚焦】越秀证券指恒指连升三日创两月高，金价再创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2603664476","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603664476?lang=zh_cn&edition=full","pubTime":"2026-01-14 11:56","pubTimestamp":1768363016,"startTime":"0","endTime":"0","summary":"金吾财讯|越秀证券发布研报指，前一交易日恒生指数收涨0.9%至26,848点，连升3日创两个月新高，主板成交额达3,152亿港元创两个半月高位。国际金价创新高带动紫金矿业升5%。美国12月CPI同比维持2.7%符合预期，核心CPI同比2.6%低于预期。中国将对美韩进口太阳能级多晶硅续征反倾销税五年。工信部强调要稳定制造业投资，自觉抵制行业\"内卷\"。全球市场方面，道指跌0.8%，标普500跌0.19%，纳指微跌0.1%。欧洲三大股指基本持平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114122957a4c1895e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114122957a4c1895e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603259","02359","601899","BK4614","HSTECH","HSI"],"gpt_icon":1},{"id":"2603668859","title":"小摩：药明康德(02359)盈喜胜预期 料市场将有正面反应","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668859","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603668859?lang=zh_cn&edition=full","pubTime":"2026-01-14 10:10","pubTimestamp":1768356602,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根大通发布研报称，药明康德(02359)经调整净利率扩张至33%亦是另一个正面惊喜; 现予目标价142港元及“增持”评级。药明康德日前发盈喜，料2025年销售同比升16%至455亿元人民币(下同)，胜该行预期2%; 经调整净利润预计同比升41%至150亿元，较该行预期高4%。该行认为，表现胜预期主要由持续的能力与产能提升、生产流程优化，以及营运效率改善所推动; 料市场对盈喜将有正面反应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2430703251.USD","LU1894683348.USD","LU0170899867.USD","BK4581","LU0320765489.SGD","LU1244550494.USD","BK4533","LU0211331839.USD","LU1162221912.USD","LU2357305700.SGD","IE00B1XK9C88.USD","LU1280957306.USD","LU0238689110.USD","LU0211328371.USD","603259","IE00BHPRN162.USD","LU0265550946.USD","LU0820562030.AUD","LU1670627923.USD","LU2237443382.USD","LU0971096721.USD","LU2552382132.HKD","02359","LU0267386448.USD","LU1119994496.HKD","LU2213496289.HKD","LU1363072403.SGD","LU1894683264.USD","LU2488822045.USD","IE00BYXW3230.USD","LU0345769128.USD","LU2125910500.SGD","LU2430703095.HKD","LU0203347892.USD","IE00B1BXHZ80.USD","LU1551013425.SGD","LU1720051017.SGD","LU2211815571.USD","LU2462157665.USD","LU0251132253.USD","LU1988902786.USD","BK1141","IE00BJLML261.HKD","LU0345770308.USD","LU1997245094.SGD","LU0203345920.USD","LU2552382058.USD","LU1064131342.USD","LU1974910355.USD","LU1551013342.USD"],"gpt_icon":0},{"id":"2603505369","title":"药明康德涨6.00%，浦银国际证券二个月前给出“买入”评级，目标价124.40元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603505369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603505369?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:33","pubTimestamp":1768289637,"startTime":"0","endTime":"0","summary":"今日药明康德涨6.00%，收盘报104.6元。2025年10月28日，浦银国际证券研究员阳景,胡泽宇发布了对药明康德的研报《3Q25业绩及新签订单增速再超预期，上调全年指引》，该研报对药明康德给出“买入”评级，认为其目标价为124.4元，现价距离目标价尚有18.93%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为79.37%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为民生证券的乔波耀。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300020376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","02359","603259"],"gpt_icon":0},{"id":"2603575538","title":"港股异动 | CRO概念股涨幅居前 药明康德(02359)去年净利预计翻倍 板块有望迎“戴维斯双击”","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575538","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575538?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:09","pubTimestamp":1768270178,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，药明康德涨8.48%，报120.2港元；凯莱英涨7.4%，报91.4港元；康龙化成涨7.13%，报24.64港元；泰格医药涨7.16%，报53港元；药明生物涨5%，报39.46港元。消息面上，1月12日晚，药明康德公布，公司全年预计实现营业收入454.56亿元，同比增长15.84%；其中，持续经营业务收入同比增长约21.40%。预计经调整归母净利润149.57亿元，同比增长约41.33%；归属于公司股东的净利润191.51亿元，同比增长约 102.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d9a285c5d35960016c392e2c485f56f0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0140636845.USD","03347","LU1720050803.USD","BK1576","LU0417516738.SGD","LU0456842615.SGD","SG9999002562.SGD","LU1808992512.USD","BK1610","LU2125910500.SGD","603259","LU0417516902.SGD","LU1997245094.SGD","02269","BK1583","LU0856984785.SGD","LU0516422366.SGD","LU1794554557.SGD","LU0708995583.HKD","LU2039709279.SGD","LU1242518857.USD","LU1997245177.USD","03759","LU0572944931.SGD","BK1141","LU3063872942.SGD","LU1997244956.HKD","SG9999002463.SGD","LU2495084118.USD","IE00B0JY6N72.USD","LU0516423091.SGD","LU2045819591.USD","BK0216","LU0456827905.SGD","LU0039217434.USD","LU0052750758.USD","LU0819121731.USD","LU1046422090.SGD","LU1934453819.USD","LU0320764599.SGD","LU0348825331.USD","02359","06821","LU0051755006.USD","LU0456846285.SGD","LU0516422440.USD","LU0588546209.SGD","LU0181495838.USD","LU0823426308.USD","LU0359201612.USD"],"gpt_icon":0},{"id":"2603575987","title":"商业航天大面积跌停，AI应用继续大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575987","media":"大河财立方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575987?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:06","pubTimestamp":1768270010,"startTime":"0","endTime":"0","summary":"大河财立方记者 夏晨翔 任浩鹏1月13日开盘，A股三大指数集体高开后震荡，医疗、CRO、生物科技、AI应用、文化传媒、虚拟人、AIGC、保险等概念涨幅居前；商业航天、卫星导航、低空经济、卫星互联网等概念跌幅居前。12日晚间，多个热门赛道概念股发布异常波动、风险提示、停牌核查公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011310120797a189a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011310120797a189a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002594","LU0543330566.HKD","LU0540923850.HKD","BK1119","09988","LU0828238088.HKD","LU0650527681.SGD","SG9999015952.SGD","BK1594","LU0417516738.SGD","LU1251922891.USD","LU1770034418.SGD","LU1880383440.USD","LU2153592121.USD","LU0634319403.HKD","LU0314109678.HKD","LU0594300179.USD","LU2476274720.SGD","LU0307460666.USD","LU0143863198.USD","LU0359201885.HKD","LU0509642566.USD","81211","LU0449509016.USD","LU0326950275.SGD","LU2097828474.EUR","LU0588546209.SGD","LU0259732245.USD","LU1242518857.USD","LU0449515922.USD","00241","301230","600151","LU0593848301.USD","LU0588545730.USD","LU0511384066.AUD","LU0327786744.USD","603598","LU2476274308.USD","LU0516422366.SGD","LU2360107325.USD","LU0039217434.USD","LU0516423174.USD","300785","LU1961090484.USD","LU0417516902.SGD","301171","BK1509","LU0865486749.SGD","SG9999002463.SGD","SG9999015945.SGD","IE00BD6J9T35.USD","BK1539","SG9999006597.SGD","SG9999014674.SGD","LU0348805143.USD","LU1794554557.SGD","01211","LU0289960550.SGD","LU1242518931.SGD","BK1522","LU0505663152.USD","BYDDY","002131","LU0588545490.SGD","LU1023057109.AUD","LU0516423091.SGD","BK1540","600880","LU0143863784.USD","LU0043850808.USD","LU0823426308.USD","LU0871576103.HKD","HYDD.SI","LU2449936058.SGD","LU0856984785.SGD","SG9999006514.SGD","LU0164865239.USD","LU2348774022.SGD","LU0605514214.HKD","LU0516422440.USD","09868","LU0463099449.HKD","LU0594300419.USD","LU0823414551.USD","603259","002149","LU0819123356.HKD","300063","LU1861214812.USD","SG9999002828.SGD","002044","LU2399975544.HKD","LU0348825331.USD","LU2778985437.USD","LU2294711713.HKD","688331","LU1861219969.SGD","SG9999015978.USD","SG9999015986.USD","601698","BK1610","LU0254981946.USD","LU0348827113.USD","LU1868837565.USD","LU2097828557.USD","LU0819121731.USD","BK1582","LU0289961442.SGD","LU2097828631.EUR","09995","LU2097828714.EUR","LU0320764599.SGD","LU0164872284.USD","002413","LU0052750758.USD","LU0229945570.USD","000547","LU0211977185.USD","LU0561508036.HKD","LU0165289439.USD","LU0823039010.USD","LU0315178854.USD","LU0269904917.USD","LU2249611893.SGD","LU2097828805.USD","LU2357125470.USD","LU0175139822.USD","LU2039709279.SGD","603986","300244","LU1868838027.USD","LU1813983027.USD","LU1880383366.USD","LU1303224171.USD","LU0708995583.HKD","LU0572944931.SGD","LU0531971595.HKD","LU0469268626.HKD","LU0054450605.USD","LU1188198961.HKD","LU1808992512.USD","LU0214875030.USD","LU1868837722.USD","LU0359202008.SGD","LU0531970944.HKD","LU0516422952.EUR","LU1720050803.USD","SG9999001226.SGD","03986","LU1328277881.USD","LU0244354667.USD","LU1719994722.HKD","LU0823038988.USD","LU0084288322.USD","600986","LU0348735423.USD","LU2506951792.HKD","LU0289739343.SGD","LU0823414478.USD","02359","LU0588545904.SGD","LU0359201612.USD","LU0979878070.USD","LU0823426480.USD"],"gpt_icon":1}],"profile":{"ret":0,"serverTime":1769977205955,"stockEarnings":[{"period":"1week","weight":-0.0246},{"period":"1month","weight":0.0503},{"period":"3month","weight":-0.0423},{"period":"6month","weight":0.027},{"period":"1year","weight":0.7628},{"period":"ytd","weight":0.0503}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0376},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.1567},{"period":"1year","weight":0.2668},{"period":"ytd","weight":0.0376}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"无锡药明康德新药开发股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"274055人(较上一季度增加16.39%)","perCapita":"9024股","listingDate":"2018-05-08","address":"江苏省无锡市滨湖区马山五号桥","registeredCapital":"298375万元","survey":" 无锡药明康德新药开发股份有限公司的主营业务是为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务。公司的主要产品是化学业务、测试业务、生物学业务。公司的服务能力和规模在行业处于领先地位,拥有了多项行业领先的技术和能力。","listedPrice":21.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明康德(603259)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明康德(603259)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明康德,603259,药明康德股票,药明康德股票老虎,药明康德股票老虎国际,药明康德行情,药明康德股票行情,药明康德股价,药明康德股市,药明康德股票价格,药明康德股票交易,药明康德股票购买,药明康德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明康德(603259)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明康德(603259)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}